Vactosertib, a Novel, Orally Bioavailable Activin Receptor-Like Kinase 5 Inhibitor, Promotes Regression of Fibrotic Plaques in a Rat Model of Peyronie's Disease
Year: 2019
Type: article
Abstract: PURPOSE: To examine the therapeutic effect of Vactosertib, a small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor (activin receptor-like kinase-5, ALK5), in an experimental model of Peyronie's disease (PD) and determining anti-fibrotic mechanisms of Vactosertib in primary fibroblasts derived from human PD plaques. MATERIALS AND METHODS: . RESULTS: by hindering the TGF-β1-induced Smad2/3 phosphorylation and nuclear translocation, and fibroblast-to-myofibroblast transdifferentiation. CONCLUSIONS: In view of the critical role of TGF-β and the Smad pathway in the pathogenesis of PD, inhibition of this pathway with an ALK5 inhibitor may represent a novel, targeted therapy for PD.
DOI: 10.5534/wjmh.190071
Authors: Kang-Moon Song(Conceptualization, Data curation, Writing – original draft), Doo Yong Chung(Conceptualization, Formal analysis, Writing – original draft), Min Ji Choi(Data curation, Software), Kalyan Ghatak(Data curation), Nguyen Nhat Minh(Data curation), Anita Limanjaya(Data curation), Mi-Hye Kwon(Formal analysis, Software), Jiyeon Ock(Formal analysis), Guo Nan Yin(Formal analysis), Dae-Kee Kim(Methodology), Ji-Kan Ryu(Conceptualization, Funding acquisition, Writing – original draft), Jun-Kyu Suh(Conceptualization, Funding acquisition, Writing – review & editing)
Institutions: Inha University, Ewha Womans University
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G3148980459, G6606338102
OpenAlex ID: W2972280418
